Literature DB >> 10213506

Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies.

P Paul1, F A Cabestré, F A Le Gal, I Khalil-Daher, C Le Danff, M Schmid, S Mercier, M F Avril, J Dausset, J G Guillet, E D Carosella.   

Abstract

Nonclassical MHC class I HLA-G antigen expression is tissue specific and is thought to play a role in tolerance of the semiallogeneic fetus by the maternal immune system. Ectopic expression of HLA-G by tumor cells provides them with an additional mechanism of escape from immunosurveillance by host cytotoxic effector mechanisms. The aim of this study was to assess the expression of nonclassical HLA-G antigens in ex vivo human melanoma biopsies. HLA-G mRNA levels corresponding to both membrane-bound and soluble protein isoforms were analyzed in tumor specimens obtained from primary or metastatic melanomas of 23 patients. High levels of HLA-G transcription were detected in tumor specimens in 5 of 23 patients and found to be comparable in both lymph node and skin metastases. HLA-G mRNA transcript levels at tumor sites in 18 of these patients were compared with those in samples of their own healthy skin and were higher in the tumor tissue in 12 patients. Differential expression of mRNA transcripts corresponding to soluble and membrane-bound HLA-G was also observed in some tumor biopsies. HLA-G protein expression was detected in tumors that exhibited high levels of HLA-G transcription by immunofluorescence of frozen sections and Western blot analysis of both tumor and healthy skin biopsies, using anti-HLA-G-specific monoclonal antibodies. This work provides evidence that HLA-G gene transcription and protein expression can be up-regulated ex vivo in melanoma. Our finding that several of the tumors studied expressed high levels of HLA-G provides additional clues as to how a tumor can be selected in vivo to escape from cytotoxic antitumor responses, constituting a new parameter to be considered in the design of therapeutic approaches aimed at enhancing antitumor immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213506

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism.

Authors:  N Lila; N Rouas-Freiss; J Dausset; A Carpentier; E D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells?

Authors:  S Aractingi; N Briand; C Le Danff; M Viguier; H Bachelez; L Michel; L Dubertret; E D Carosella
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Authors:  Karl-Johan Malmberg; Victor Levitsky; Håkan Norell; Cristina Teixeira de Matos; Mattias Carlsten; Kjell Schedvins; Hodjattallah Rabbani; Alessandro Moretta; Kalle Söderström; Jelena Levitskaya; Rolf Kiessling
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  The HLA-G genotype is associated with IL-10 levels in activated PBMCs.

Authors:  Roberta Rizzo; Thomas Vauvert F Hviid; Marina Stignani; Alessandra Balboni; Maria Teresa Grappa; Loredana Melchiorri; Olavio R Baricordi
Journal:  Immunogenetics       Date:  2005-04-02       Impact factor: 2.846

5.  Impact of HLA-G in the outcome of vitiligo in Tunisian patients.

Authors:  Akrem Jalel; Aouadi Ridha; Duboisier Laurent; Moureaux Philippe; M H Hamdaoui
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

6.  In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner.

Authors:  Philippe Rousseau; Krzysztof Masternak; Michal Krawczyk; Walter Reith; Jean Dausset; Edgardo D Carosella; Philippe Moreau
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

7.  HLA-G does not have a pathophysiological role in Graves' disease.

Authors:  E H Kemp; R A Metcalfe; P F Watson; A P Weetman
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

8.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Martina Skrede; Hiep Phuc Dong; Søren Nielsen; Michael T McMaster; Jahn M Nesland; Ie-Ming Shih; Ben Davidson
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

9.  HLA-G gene repression is reversed by demethylation.

Authors:  Philippe Moreau; Gael Mouillot; Philippe Rousseau; Celine Marcou; Jean Dausset; Edgardo D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

10.  Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma.

Authors:  El Chérif Ibrahim; Yves Allory; Frédéric Commo; Bernard Gattegno; Patrice Callard; Pascale Paul
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.